Risk of ovarian cancer in relation to use of phenolphthalein-containing laxatives

British Journal of Cancer

Volumn 83, Issue 3, 2000, Pages 404-406

  Cooper, G S ^a   Longnecker, M P ^a   Sandler, D P ^a   Ness, R B ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Laxatives; Ovarian cancer; Phenolphthalein

Indexed keywords

LAXATIVE; PHENOLPHTHALEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; UNITED STATES;

EID: 0033949720     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1250     Document Type: Article

References (11)

1. Bo-Linn GW, Santa Ana CA, Morawski SG and Fordtran JS (1983) Purging and caloric absorption in bulimic patients and normal women. Ann Intern Med 99: 14-17
2. Bytzer P, Stokholm M, Andersen I, Klitgaard NA and Schaffalitzky de Muckadell OB (1989) Prevalence of surreptitious laxative abuse in patients with diarrhoea of uncertain origin: a cost benefit analysis of a screening procedure. Gut 30: 1379-1384
3. De Smet PH and Wagenaar HW (1998) Weight reduction preparation from Thailand: unexpected complication for the traveler. Ned Tijdschr Geneeskd 142: 2798-2800
4. Dunnick JK and Hailey JR (1996) Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res 56: 4922-4926
5. Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-Machacek EM, Foley JF, Lacks GD, Stasiewicz S and French JE (1997) Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-dcficient (±) mice. Toxic Pathol 25: 533-540
6. Food and Drug Administration. Laxative drug products for over-the-counter human use (1999). Federal Register 64: 4535-4540
7. National Toxicology Program (1996) NTP technical report on the toxicology and carcinogenesis studies of phenolphthalein (CAS no. 77-09-8) in F344/N rats and B6C3F1R mice (feed studies). Research Triangle Park, NC: US Dept of Health and Human Services, Public Health Service, National Institutes of Health; Springfield, VA.: Available from the National Technical Information Service
8. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, Morgan M, Wheeler JE and the SHARE Study Group (in press). Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol
9. Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements. 11th edition. Montvale, NJ: Medical Economics Company, Inc. 1990
10. Ravdin PM, van Beurden M and Jordan VC (1987). Estrogenic effects of phenolphthalein on human breast cancer cells in vitro. Breast Cancer Res Treat 9: 151-154
11. WHO Pharmaceutical Newsletter (1998). Laxatives containing phenolphthalein -voluntary withdrawal. Nos. 1-2, 4-15